Sydney School of Public Health, University of Sydney, Sydney, Australia.
Am J Kidney Dis. 2011 Mar;57(3):476-87. doi: 10.1053/j.ajkd.2010.11.018. Epub 2011 Jan 22.
Cardiovascular disease is the leading cause of death after kidney transplant. Screening for coronary artery disease is integral to pretransplant evaluation, although the relative performance of different tests is uncertain.
Systematic review of diagnostic test accuracy studies using hierarchical summary receiver operating characteristic analysis.
SETTING & POPULATION: Kidney transplant candidates undergoing pretransplant assessment. SELECTION CRITERIA OF STUDIES: Studies evaluating the accuracy of screening tests for detecting coronary artery disease.
Any non- or minimally invasive test used to diagnose coronary artery disease.
Coronary angiography.
11 studies (690 participants) evaluated dobutamine stress echocardiography; 7 (317 participants), myocardial perfusion scintigraphy; 2 (129 participants), exercise stress electrocardiography; and 2 (121 participants), other tests. Dobutamine stress echocardiography had pooled sensitivity of 0.80 (95% CI, 0.64-0.90) and specificity of 0.89 (95% CI, 0.79-0.94). Myocardial perfusion scintigraphy had pooled sensitivity of 0.69 (95% CI, 0.48-0.85) and specificity of 0.77 (95% CI, 0.59-0.89). Head-to-head comparison of dobutamine stress echocardiography and myocardial perfusion scintigraphy (2 studies; 116 participants) showed that dobutamine stress echocardiography had higher specificity and at least equivalent or higher sensitivity. Indirect comparison suggested dobutamine stress echocardiography may have improved accuracy over myocardial perfusion scintigraphy (P = 0.07).
Power to detect differences in accuracy between tests is limited due to sparse data. Absence of significant coronary artery disease may not necessarily correlate with cardiac event-free survival after transplant.
Dobutamine stress echocardiography may perform better than myocardial perfusion scintigraphy; however, additional studies directly comparing dobutamine stress echocardiography and myocardial perfusion scintigraphy are needed. Further research should focus on assessing the ability of functional tests to predict postoperative outcome.
心血管疾病是肾移植后的主要致死原因。在移植前评估中,筛查冠状动脉疾病是不可或缺的,尽管不同检测方法的相对性能尚不确定。
使用分层综合受试者工作特征分析进行诊断检测准确性的系统综述。
接受移植前评估的肾移植候选者。
评估用于诊断冠状动脉疾病的筛查检测准确性的研究。
用于诊断冠状动脉疾病的任何非侵入性或微创性检测。
冠状动脉造影。
11 项研究(690 名参与者)评估了多巴酚丁胺负荷超声心动图;7 项研究(317 名参与者)评估了心肌灌注闪烁显像;2 项研究(129 名参与者)评估了运动应激心电图;2 项研究(121 名参与者)评估了其他检测。多巴酚丁胺负荷超声心动图的敏感性为 0.80(95%置信区间,0.64-0.90),特异性为 0.89(95%置信区间,0.79-0.94)。心肌灌注闪烁显像的敏感性为 0.69(95%置信区间,0.48-0.85),特异性为 0.77(95%置信区间,0.59-0.89)。多巴酚丁胺负荷超声心动图和心肌灌注闪烁显像的头对头比较(2 项研究,116 名参与者)表明,多巴酚丁胺负荷超声心动图的特异性更高,并且至少具有等效或更高的敏感性。间接比较表明,多巴酚丁胺负荷超声心动图的准确性可能优于心肌灌注闪烁显像(P=0.07)。
由于数据稀疏,检测检测方法准确性差异的能力有限。没有明显的冠状动脉疾病不一定与移植后无心脏事件的生存相关。
多巴酚丁胺负荷超声心动图的性能可能优于心肌灌注闪烁显像;然而,需要直接比较多巴酚丁胺负荷超声心动图和心肌灌注闪烁显像的额外研究。进一步的研究应侧重于评估功能检测预测术后结果的能力。